Pathways of Reconciliation

Pathways of Reconciliation

Author: Aimée Craft

Publisher: Univ. of Manitoba Press

Published: 2020-05-29

Total Pages: 394

ISBN-13: 0887558550

DOWNLOAD EBOOK

Since the Truth and Reconciliation Commission released its Calls to Action in June 2015, governments, churches, non-profit, professional and community organizations, corporations, schools and universities, clubs and individuals have asked: “How can I/we participate in reconciliation?” Recognizing that reconciliation is not only an ultimate goal, but a decolonizing process of journeying in ways that embody everyday acts of resistance, resurgence, and solidarity, coupled with renewed commitments to justice, dialogue, and relationship-building, Pathways of Reconciliation helps readers find their way forward. The essays in Pathways of Reconciliation address the themes of reframing, learning and healing, researching, and living. They engage with different approaches to reconciliation (within a variety of reconciliation frameworks, either explicit or implicit) and illustrate the complexities of the reconciliation process itself. They canvass multiple and varied pathways of reconciliation, from Indigenous and non-Indigenous perspectives, reflecting a diversity of approaches to the mandate given to all Canadians by the TRC with its Calls to Action. Together the authors — academics, practitioners, students and ordinary citizens — demonstrate the importance of trying and learning from new and creative approaches to thinking about and practicing reconciliation and reflect on what they have learned from their attempts (both successful and less successful) in the process.


Patently Innovative

Patently Innovative

Author: R A Bouchard

Publisher: Elsevier

Published: 2012-01-02

Total Pages: 298

ISBN-13: 1908818085

DOWNLOAD EBOOK

Patently innovative provides a review of the importance of traditional patent law and emerging linkage regulations for pharmaceutical products on the global stage, with a focus on the linkage regime in Canada. The primary focus is on how innovation in the pharmaceutical sector can be strongly regulated and how government regulation can either stimulate or inhibit development of breakthrough products. - Includes empirical research to relate innovation to drug law - A multidisciplinary approach is taken, including the intersection of IP (intellectual property) law, drug law and innovation - Discusses the impact of government regulation on firm innovation


Private Profits versus Public Policy

Private Profits versus Public Policy

Author: Joel Lexchin

Publisher: University of Toronto Press

Published: 2016-01-01

Total Pages: 385

ISBN-13: 1442626593

DOWNLOAD EBOOK

In his new work, Private Profits versus Public Policy, Joel Lexchin addresses this question as he examines how public policy with respect to the pharmaceutical industry has evolved in Canada over the past half century.


Uncle Sam and Us

Uncle Sam and Us

Author: Stephen Clarkson

Publisher: University of Toronto Press

Published: 2002-01-01

Total Pages: 546

ISBN-13: 9780802085399

DOWNLOAD EBOOK

Analyzing the Mulroney-Chr?tien era's impact on Canadian governance through globalization from without and neoconservatism from within, Clarkson brings together a comprehensive understanding of the current Canadian political climate.


Profit Is Not the Cure

Profit Is Not the Cure

Author: Maude Barlow

Publisher: McClelland & Stewart

Published: 2011-02-18

Total Pages: 271

ISBN-13: 1551995263

DOWNLOAD EBOOK

On July 12, 1966, the Medical Care Insurance Act was passed by the federal House of Commons after a ferocious public debate that pitted the vast majority of Canadians against a powerful alliance of business, insurance companies, and doctors. More than thirty years later, the same battle is being fought all over again. Only now, the forces opposed to medicare are more ideologically unified, more richly endowed, and tied to transnational corporations whose power exceeds that of entire countries. In Profit Is Not the Cure, Maude Barlow traces the history of medicare in Canada. She compares it with both public and private systems in other parts of the world. And she contrasts it with the brutally divisive system that exists in the United States, where forty-four million people have no medical insurance, and millions more get minimal care through profit-driven health maintenance organizations. From the point of view of most patients, the United States health-care model is a disaster. But the proponents of privatization in Canada, supported by the right-wing media and corporate lobbyists, are determined to impose American-style “reforms” on the Canadian public. Three provinces – British Columbia, Alberta, and Ontario – are moving ahead rapidly to enlarge the role of commerce in the provision of health-care services. They are introducing user fees, delisting procedures that previously were covered, and encouraging private corporations to move into areas that used to be the exclusive domain of the public system. While the prime minister and federal cabinet have paid lipservice to the principles of medicare, they have made it clear by their actions that they will do nothing to impede the destruction of those principles by the provinces. In fact, their enthusiastic support of NAFTA, and the impending Free Trade Agreement of the Americas (FTAA) and General Agreement on Trade in Services (GATS), has made the defence of medicare increasingly difficult. Canadians overwhelmingly support medicare. Many, however, have been persuaded that it is a luxury we can no longer afford. Maude Barlow argues that this proposition is wrong. An earlier generation fought a bitter battle to bring medicare into existence. Another battle must be fought now to save it. But we owe it to the founders of the system, as well as to future generations, to take up the cause again. This important book shows the way.


Science and Social Context

Science and Social Context

Author: Lisa N. Mills

Publisher: McGill-Queen's Press - MQUP

Published: 2002-05-28

Total Pages: 222

ISBN-13: 0773570276

DOWNLOAD EBOOK

She examines the decision-making processes at Monsanto that led to their making the drug available and discusses corporate, academic, and regulatory decision-making in the context of a restructured global political economy for agriculture. Mills shows that there was consensus about the scientific evidence but interpretation of that evidence differed depending on the context from which it was viewed. Scientists who analysed it for regulatory bodies interpreted it differently than scientists in corporate or academic institutions, and scientists in Canada and Europe interpreted it differently than those in the United States. In the United States it was assumed that any problems arising from its use could be taken care of within the existing dairy system; in Canada and Europe these problems were regarded as legitimate animal welfare issues. While all regulatory bodies agreed that human health problems were unlikely, in Canada the Health Protection Branch questioned this, but ultimately rejected the drug on animal health grounds.